| Name | Recombinant Human BMP-7 |
| Purity | Greater than 95% as determined by reducing SDS-PAGE |
| Endotoxin level | <1 EU/µg as determined by LAL test. |
| Construction | Recombinant Human Bone morphogenetic protein 7 is produced by our Mammalian expression system and the target gene encoding Ser293-His431 is expressed. |
| Accession # | P18075 |
| Host | Human Cells |
| Species | Human |
| Predicted Molecular Mass | 15.5 KDa |
| Buffer | Supplied as a 0.2 μm filtered solution of 20mM PB, 100mM NaCl, 5% Mannitol,0.05% Tween80, pH7.5. |
| Form | Liquid |
| Shipping | The product is shipped on dry ice/polar packs.Upon receipt, store it immediately at the temperature listed below. |
| Stability&Storage | Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles. |
Alternative Names
Bone morphogenetic protein 7; BMP-7; Osteogenic protein 1 (OP-1); Eptotermin alfa; BMP7; OP1
Background
Bone morphogenetic protein 7 (BMP7), also known as osteogenic protein-1 (OP-1) is a member of Transforming growth factor-β (TGF-β) family of proteins. Bone morphogenetic proteins were discovered in 1965 by Marshal Urist, of which BMP7 is of particular interest in this review being a leptin-independent anorexinogen and having role in energy expenditure in the brown adipose tissue, which makes it a potential target for preventing/treating obesity. As it has been established that Obesity displays a state of leptin-resistance, thus a protein-like BMP7 which acts through a leptin-independent pathway could give new therapeutic directions.
Note
For Research Use Only , Not for Diagnostic Use.